Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Operating Leases (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Operating Leases for 7 consecutive years, with $43.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 8.46% to $43.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.6 million through Dec 2025, up 8.46% year-over-year, with the annual reading at $43.6 million for FY2025, 8.46% up from the prior year.
  • Operating Leases hit $43.6 million in Q4 2025 for Immunocore Holdings, up from $43.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $44.4 million in Q2 2025 to a low of $33.1 million in Q4 2022.
  • Historically, Operating Leases has averaged $38.9 million across 5 years, with a median of $40.2 million in 2024.
  • Biggest five-year swings in Operating Leases: decreased 3.06% in 2022 and later rose 27.48% in 2025.
  • Year by year, Operating Leases stood at $34.2 million in 2021, then dropped by 3.06% to $33.1 million in 2022, then increased by 7.48% to $35.6 million in 2023, then grew by 12.78% to $40.2 million in 2024, then increased by 8.46% to $43.6 million in 2025.
  • Business Quant data shows Operating Leases for IMCR at $43.6 million in Q4 2025, $43.3 million in Q3 2025, and $44.4 million in Q2 2025.